Table 3.
Primary versus recurrent GBM sample categorical variables.
| Variable | Group | n | n total | Percent % | p value |
|---|---|---|---|---|---|
| Male | Primary | 23 | 38 | 60.53 | 1.0 |
| Recurrent | 7 | 11 | 63.64 | ||
| ATRX mutated | Primary | 7 | 38 | 18.42 | 1.0 |
| Recurrent | 2 | 11 | 18.18 | ||
| p53 mutated | Primary | 10 | 37 | 27.03 | 0.7075 |
| Recurrent | 4 | 11 | 36.36 | ||
| IDH1 mutated | Primary | 5 | 38 | 13.16 | 0.1786 |
| Recurrent | 4 | 11 | 36.36 | ||
| MGMT methylated | Primary | 6 | 19 | 31.58 | 0.3500 |
| Recurrent | 1 | 1 | 100 |
The patient gender, the clinically relevant mutations (ATRX, p53, IDH-1) and MGMT methylation status are shown by primary or recurrent tumor status. No statistically significant differences were found between the primary or recurrent samples in these variables.